NCT07058675View on ClinicalTrials.gov

Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility

NACompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

June 18, 2025

Conditions

PCOS

Interventions

DRUG

Metformin Hydrochloride 500 MG

metformin (MET) hydrochloride 500 mg three times daily as the standard insulin sensitizer.

DRUG

Myoinositol

myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily

Trial Locations (1)

13511

Benha university, Banhā

All Listed Sponsors

lead

Benha University

OTHER

NCT07058675 - Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility | Biotech Hunter | Biotech Hunter